Revenue growth and raised guidance signal strong execution, but widening net losses and EPS miss temper the outlook. Monitor next quarter for margin trajectory and progress on new product launches (delirium monitoring, next-gen hardware) which are not included in current guidance.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $27.39entry
- T+1 · 13d ago −5.04%α −0.63% · $26.01
- T+5 · 7d ago +1.50%α +2.41% · $27.80
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Ceribell reported Q3 2026 revenue of $29.3M (+30% YoY), slightly above the $29.2M consensus, but GAAP EPS of -$0.55 missed the -$0.52 consensus. The company raised its full-year 2026 revenue guidance to $115M-$117M, reflecting continued momentum in its core seizure business and new account additions.
Key Financial Metrics
Key Facts
- Total revenue $29.3M, +30% YoY vs $22.6M (consensus $29.2M)
- GAAP net loss per share -$0.55 vs consensus -$0.52 (miss)
- Product revenue $22.2M (+31% YoY), subscription revenue $7.1M (+28% YoY)
- Gross margin 90%, up from 88% in prior year
- Full-year 2026 revenue guidance raised to $115M-$117M (prior range not stated)
- Adjusted EBITDA loss -$12.1M vs -$9.2M in Q3 2025
- Cash and marketable securities $117.5M; new $60M credit facility entered in August 2026
- Record 35 net new customer accounts added in the quarter, total 747 active accounts
Financial Impact
Revenue beat consensus by ~$0.1M (0.3%); EPS miss by $0.03 (5.8%); guidance raised by undisclosed amount
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product | $22.2M | +30.6% |
| Subscription | $7.1M | +27.6% |
Risk Factors
- Net loss widened to $21.4M from $13.5M, with operating expenses growing 36% vs revenue growth of 30%
- EPS miss of $0.03 vs consensus; Street may focus on bottom-line deterioration
- Guidance excludes contributions from neonate, pediatric, and delirium products, limiting upside visibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394780 |
Track record
39 reports on CBLL
7 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +17.06% at T+60 after the Feb 23, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $26.09 Now $26.42 +1.26% settles Nov 19
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $26.42 Now $26.42 +0.00% settles Nov 18
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $26.42 to $25.97 Now $26.42 +0.00% ▼ −1.70% −0.69% vs SPY
- Nov 13, 20264d ago Insider Cluster Neutral 2/10 Entry $26.42 to $25.97 Now $26.42 +0.00% ▼ −1.70% −0.69% vs SPY
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $26.14 to $26.42 Now $26.42 +1.07% ▲ +1.07% +2.98% vs SPY
- Nov 10, 20267d ago Insider Cluster Neutral 2/10 Entry $27.80 to $26.35 Now $26.42 −4.96% ▼ −5.22% −4.86% vs SPY
- Nov 9, 20268d ago 144 Neutral 2/10 Entry $27.60 to $27.48 Now $26.42 −4.28% ▼ −0.43% −0.07% vs SPY
- Nov 3, 202614d ago 8-K Neutral 5/10 No price data
- Nov 3, 202614d ago Press Release Neutral 5/10 Viewing Entry $27.39 to $26.01 Now $26.42 −3.54% ▼ −5.04% −0.63% vs SPY
- Nov 2, 202615d ago 144 Neutral 2/10 Entry $26.96 to $28.27 Now $26.42 −2.00% ▲ +4.86% +4.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers